Monocyte Chemotactic Protein-1 (MCP-1) as a Predictor of Prolonged Urinary Incontinence After Radical Prostatectomy
M. Liss, T. Ahlering, B. Morales, A. Gordon, K. Osann, D. Skarecky, A. Lusch, F. Zaldivar, G. Ghoniem
{"title":"Monocyte Chemotactic Protein-1 (MCP-1) as a Predictor of Prolonged Urinary Incontinence After Radical Prostatectomy","authors":"M. Liss, T. Ahlering, B. Morales, A. Gordon, K. Osann, D. Skarecky, A. Lusch, F. Zaldivar, G. Ghoniem","doi":"10.2174/1874303X01609010044","DOIUrl":null,"url":null,"abstract":"Author(s): Liss, MA; Ahlering, TE; Morales, B; Gordon, A; Osann, K; Skarecky, D; Lusch, A; Zaldivar, F; Ghoniem, GM | Abstract: © Liss et al. Objectives: To investigate monocyte chemotactic protein-1 (MCP-1) as a novel urinary biomarker to predict prolonged post prostatectomy incontinence. Methods: Men submitted urine samples prior to robotic radical prostatectomy. MCP-1 values were derived using an ELISA test. Pad usage at 7, 30, and 60 days were documented by patient post cards mailed when zero pads was reached. The primary outcome was defined as no incontinence pad usage at 30 days at prostatectomy. Results: After exclusions, 76 patients were included in analyses. Continence was reached by 29% (22/76), 56% (42/76), and (75/76) 98% at 7, 30, and 60 days, respectively. The average MCP-1 (p=0.258) was not different between the continent and incontinent groups. Highest quartile of MCP-1 (MCP g 166 pg/mL) and normalized MCP-1 (MCP-1/TV g0.53) noted a significant delay in continence at 30 days (p=0.050 and p=0.003). Only 26% (5/19) in the highest MCP1/TV quartile were continent, whereas 65% (37/57) of men in the 3 lower quartiles reached zero pad continence (p=0.003). In a logistic regression model the highest quartile of MCP1/TV had a significant chance of being incontinent at 30 days (OR 0.22; 95% CI 0.058-0.80; p=0.022). Conclusion: MCP-1/TV is a urinary biomarker that may predict prolonged urinary incontinence after radical prostatectomy.","PeriodicalId":38952,"journal":{"name":"Open Urology and Nephrology Journal","volume":"9 1","pages":"44-50"},"PeriodicalIF":0.0000,"publicationDate":"2016-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Open Urology and Nephrology Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1874303X01609010044","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 3
Abstract
Author(s): Liss, MA; Ahlering, TE; Morales, B; Gordon, A; Osann, K; Skarecky, D; Lusch, A; Zaldivar, F; Ghoniem, GM | Abstract: © Liss et al. Objectives: To investigate monocyte chemotactic protein-1 (MCP-1) as a novel urinary biomarker to predict prolonged post prostatectomy incontinence. Methods: Men submitted urine samples prior to robotic radical prostatectomy. MCP-1 values were derived using an ELISA test. Pad usage at 7, 30, and 60 days were documented by patient post cards mailed when zero pads was reached. The primary outcome was defined as no incontinence pad usage at 30 days at prostatectomy. Results: After exclusions, 76 patients were included in analyses. Continence was reached by 29% (22/76), 56% (42/76), and (75/76) 98% at 7, 30, and 60 days, respectively. The average MCP-1 (p=0.258) was not different between the continent and incontinent groups. Highest quartile of MCP-1 (MCP g 166 pg/mL) and normalized MCP-1 (MCP-1/TV g0.53) noted a significant delay in continence at 30 days (p=0.050 and p=0.003). Only 26% (5/19) in the highest MCP1/TV quartile were continent, whereas 65% (37/57) of men in the 3 lower quartiles reached zero pad continence (p=0.003). In a logistic regression model the highest quartile of MCP1/TV had a significant chance of being incontinent at 30 days (OR 0.22; 95% CI 0.058-0.80; p=0.022). Conclusion: MCP-1/TV is a urinary biomarker that may predict prolonged urinary incontinence after radical prostatectomy.
单核细胞趋化蛋白-1 (MCP-1)作为根治性前列腺切除术后长期尿失禁的预测因子
作者:Liss, MA;Ahlering TE;莫拉莱斯,B;戈登,;Osann K;Skarecky D;Lusch,;萨尔迪瓦尔,F;摘要:©Liss等。目的:探讨单核细胞趋化蛋白-1 (MCP-1)作为预测前列腺切除术后长期尿失禁的一种新的尿液生物标志物。方法:男性在机器人根治性前列腺切除术前提交尿液样本。MCP-1值采用ELISA法测定。在第7、30和60天时,通过患者明信片记录Pad的使用情况。主要结果定义为前列腺切除术后30天无尿失禁垫使用。结果:排除后,76例患者纳入分析。在7天、30天和60天,尿失禁率分别为29%(22/76)、56%(42/76)和75% /76 98%。尿失禁组和尿失禁组的平均MCP-1差异无统计学意义(p=0.258)。最高四分位数的MCP-1 (MCP g 166 pg/mL)和标准化的MCP-1 (MCP-1/TV g0.53)在30天的尿失禁有显著延迟(p=0.050和p=0.003)。在MCP1/TV最高的四分位数中,只有26%(5/19)的男性尿失禁,而在3个较低的四分位数中,65%(37/57)的男性尿失禁为零(p=0.003)。在逻辑回归模型中,MCP1/TV的最高四分位数在30天出现尿失禁的几率显著(OR 0.22;95% ci 0.058-0.80;p = 0.022)。结论:MCP-1/TV是一种可预测根治性前列腺切除术后尿失禁持续时间的生物标志物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。